News
Pfizer lifts profit view as cuts offset flat sales outlook
Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a vaccine for Covid constituted “the biggest success that anyone could dream of having,” he said, which will undoubtedly be his legacy at the company.
Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.
The controversial move affects development of vaccines against COVID-19, flu and H5N1, drawing criticism from public health ...
Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
The Department of Health and Human Services will cancel contracts and pull funding for some vaccines that are being developed ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
MedPage Today on MSN1d
Did FDA Pick the Wrong COVID Vaccine Strain Last Season?The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...
Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Free Malaysia Today on MSN13h
Pfizer’s earnings boosted by Covid-19 products, lower expensesPfizer was among the 17 companies that received a July 31 letter from president Donald Trump demanding lower drug prices.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback